Androgen Deprivation Therapy in Prostate Cancer Increases Risk of Death from Heart Disease in Older Men
Androgen deprivation therapy (ADT) is one of the most common treatments for prostate cancer.
ADT works by blocking the level of circulating androgens (male hormones) – the ones that can fuel the growth of prostate cancers.
According to a research team from Dana-Farber Cancer Institute, Brigham and Women’s Hospital and other institutions, ADT may increase the risk of death from heart disease mortality in prostate cancer patients above age 65.
Such findings have been reported at the recent Prostate Cancer Symposium- sponsored by the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology and the Society of Urologic Oncology - in Orlando, Florida.
According to the study’s lead author, Henry Tsai, MD, a resident physician at Dana-Farber, Brigham and Women’s and the Harvard Radiation Oncology Program:
“Androgen deprivation therapy is associated with elevated body mass index, increased body fat deposits and diabetes, all of which raise the risk of death from heart diseases.”
Findings of this study should help oncologist in weighing the benefits of ADT and the risk of heart disease before administering to elderly prostate cancer patients.
Find more details from the full report.
Tags: androgen, androgen-deprivation-therapy, prostate-cancer, Prostate-Cancer-SymposiumRelated Stories
POSTED IN: on prostate cancer
0 opinions for Androgen Deprivation Therapy in Prostate Cancer Increases Risk of Death from Heart Disease in Older Men
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: